Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Debt (2020 - 2022)

Mereo BioPharma (MREO) has disclosed Total Debt for 3 consecutive years, with $486000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Total Debt fell 97.49% to $486000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $486000.0, a 97.49% decrease, with the full-year FY2021 number at $19.4 million, down 6.46% from a year prior.
  • Total Debt was $486000.0 for Q4 2022 at Mereo BioPharma, down from $19.4 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $21.3 million in Q4 2020 to a low of $486000.0 in Q4 2022.
  • A 3-year average of $13.7 million and a median of $19.4 million in 2021 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: fell 9.03% in 2021, then tumbled 97.49% in 2022.
  • Mereo BioPharma's Total Debt stood at $21.3 million in 2020, then dropped by 9.03% to $19.4 million in 2021, then crashed by 97.49% to $486000.0 in 2022.
  • Per Business Quant, the three most recent readings for MREO's Total Debt are $486000.0 (Q4 2022), $19.4 million (Q4 2021), and $21.3 million (Q4 2020).